FDA authorizes new Covid antibody drug to fight omicron variant

Indonesia Berita Berita

FDA authorizes new Covid antibody drug to fight omicron variant
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 NBCNews
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 86%

The FDA has cleared a new antibody drug, that targets the omicron variant, for adults and adolescent patients with mild-to-moderate cases.

But late last month the FDA revoked its emergency use authorization for Regeneron’s antibody drug, along with Lilly’s. The two medications had been the the backbone of antibody treatment, and doctors were hard pressed to come up with fallbacks when they didn’t work against omicron.

Alternate therapies, including antiviral pills from Pfizer and Merck, have been in short supply. An antibody drug from GlaxoSmithKline that remains effective against omicron is also scarce.Under the U.S. contract with Lilly, the government will receive about 300,000 treatment courses of the new antibody drug in February and another 300,000 in March.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

NBCNews /  🏆 10. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

FDA delays public meeting for COVID-19 vaccine for children under 5 to review more dataFDA delays public meeting for COVID-19 vaccine for children under 5 to review more dataBREAKING: The FDA has delayed a public meeting for a COVID-19 vaccine for children under 5 in order to review more data.
Baca lebih lajut »

FDA delays public meeting for COVID-19 vaccine for children under 5 to review more dataFDA delays public meeting for COVID-19 vaccine for children under 5 to review more dataThe FDA has delayed a public meeting for a COVID-19 vaccine for children under 5 in order to review more data.
Baca lebih lajut »

FDA delays public meeting for COVID-19 vaccine for children under 5 to review more dataFDA delays public meeting for COVID-19 vaccine for children under 5 to review more dataThe FDA has delayed a public meeting for a COVID-19 vaccine for children under 5 in order to review more data.
Baca lebih lajut »

U.S. to buy 600,000 doses of Eli Lilly COVID treatmentU.S. to buy 600,000 doses of Eli Lilly COVID treatmentThe U.S. is set to buy 600,000 doses of Eli Lilly’s developmental drug bebtelovimab, an antibody treatment that’s been found to neutralize COVID variants including Omicron.
Baca lebih lajut »

Young kids’ COVID vaccines create approval dilemma for FDAYoung kids’ COVID vaccines create approval dilemma for FDATwo doses of Pfizer's vaccine showed mixed results in trials, but the agency is considering approving it anyways in anticipation that a future third shot will provide children with strong immunity.
Baca lebih lajut »



Render Time: 2025-03-24 16:19:45